ZIM Laboratories Limited (ZIMLAB.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹133.82 (+5.63%) as of
Key statistics
- Market cap
- 7.17B
- P/E (TTM)
- 163.20
- EPS (TTM)
- 0.82
- Dividend yield
- 0.00%
- 52-week range
- 59.31 – 159.81
- Beta
- 0.82
- Revenue (TTM)
- 3.97B
- Profit margin
- 0.93%
- Volume
- 106.56k
About ZIM Laboratories Limited
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Nagpur, India
- Employees
- 632
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.